This review mainly discusses how these BrM-specific circumstances lead to unique interactions between anti-tumor responses generated against the extracranial disease and BrM, and how this is impacted by the characteristics of the brain-associated lymphatic system. The gene discussed is SMARCA2; the disease is neoplasm.